Mineralys surges as blood pressure drug meets trial goals

Drug developer Mineralys Therapeutics' MLYS.O shares surge 50.42% to $15.82 premarket

MLYS says its experimental drug, lorundrostat, met the main goals of mid-and late-stage trials

In the late-stage trial, co's drug reduced blood pressure by 9.1 mmHg (millimeters of mercury) at 6 weeks, compared with placebo

Lorundrostat inhibits production of aldosterone, a hormone that can contribute to high blood pressure

In the mid-stage trial, the drug reduced blood pressure by placebo-adjusted 7.9 mmHg

Stock has fallen 24.7% in the last 12 months